ResearchProjects

HCV – Source Patient Identification and Group Overlap Treatment
Funded by: Gilead - Conquering Hepatitis via Micro-Elimination (CHIME)
Project dates: May 2019 - December 2021
Principal Investigator: Eckhardt, Benjamin
PROJECT DESCRIPTION

This proof-of-concept study aimed to evaluate a partner services case findings and treatment strategy to achieve injection network level hepatitis C micro-elimination.

After identification of incident HCV infection the partner services model included:

  1. Evaluation of the incident infections injection network utilizing proximal partner identification
  2. Incentivized partner linkage and screening
  3. Transmission root evaluation utilizing next-generation HCV sequencing, and
  4. Injection network overlap treatment.
Related Publications
Eckhardt B, Aponte-Melendez Y, Kapadia SN, Mateu-Gelabert P (2022).
Contact tracing in acute hepatitis C: The source patient identification and group overlap therapy proof-of-concept pilot program
Clinical Liver Disease, 20 (2), 72-76. doi: 10.1002/cld.1242. PMCID: PMC9405500.

Katzman C, Mateu-Gelabert P, Kapadia SN, Eckhardt BJ (2019).
Contact tracing for hepatitis C: The case for novel screening strategies as we strive for viral elimination
International Journal of Drug Policy, 72, 33-39. doi: 10.1016/j.drugpo.2019.04.003. PMCID: PMC6717536.

browse all projects